Source 1primary paper2026MED
Toolkit/CAR-macrophages
CAR-macrophages
Also known as: CAR-M, CAR-Ms, Chimeric antigen receptor macrophages
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
CARmacrophages (CAR-M) ... not only phagocytose tumor cells and present antigens but also remodel the immunosuppressive tumor microenvironment
Usefulness & Problems
Why this is useful
CAR-macrophages are macrophages engineered with chimeric antigen receptors. The abstract includes them as one of the diversified CAR modalities covered by the review.; expanded CAR modality coverage; CAR-macrophages are presented as an alternative CAR-engineered immune-cell platform for cancer treatment. The abstract states that they phagocytose tumor cells, present antigens, and remodel the immunosuppressive tumor microenvironment.; cancer immunotherapy; tumor microenvironment remodeling; CAR-macrophages are engineered macrophages that use CAR signaling to directly target tumor cells while also remodeling the tumor microenvironment. The abstract presents them as a cell-based immunotherapy approach for solid tumors.; solid tumor immunotherapy; direct tumor cell targeting; CAR-macrophages are listed as an emerging CAR-based approach for autoimmune diseases. The abstract includes them within the broader set of engineered immune-cell therapies.; autoimmune disease treatment
Source:
CAR-macrophages are macrophages engineered with chimeric antigen receptors. The abstract includes them as one of the diversified CAR modalities covered by the review.
Source:
expanded CAR modality coverage
Source:
CAR-macrophages are presented as an alternative CAR-engineered immune-cell platform for cancer treatment. The abstract states that they phagocytose tumor cells, present antigens, and remodel the immunosuppressive tumor microenvironment.
Source:
cancer immunotherapy
Source:
tumor microenvironment remodeling
Source:
CAR-macrophages are engineered macrophages that use CAR signaling to directly target tumor cells while also remodeling the tumor microenvironment. The abstract presents them as a cell-based immunotherapy approach for solid tumors.
Source:
solid tumor immunotherapy
Source:
direct tumor cell targeting
Source:
tumor microenvironment remodeling
Source:
CAR-macrophages are listed as an emerging CAR-based approach for autoimmune diseases. The abstract includes them within the broader set of engineered immune-cell therapies.
Source:
autoimmune disease treatment
Problem solved
They represent an alternative immune-cell chassis within the CAR-engineering landscape.; extends CAR engineering to macrophage-based cell therapy; They are being investigated to address limitations of conventional CAR-T therapy, especially the challenge of treating solid tumors.; addresses limitations of conventional CAR-T therapy including challenges in solid tumors; The tool is intended to improve treatment of hard-to-treat solid malignancies by combining direct tumor targeting with macrophage-mediated microenvironment remodeling. It is positioned as a potential alternative to existing cell-based therapies.; providing a potential alternative cell-based therapy for solid tumors; They are presented as part of a targeted therapeutic strategy beyond conventional immunosuppression.; targeted immune-cell-based intervention in autoimmune disease
Source:
They represent an alternative immune-cell chassis within the CAR-engineering landscape.
Source:
extends CAR engineering to macrophage-based cell therapy
Source:
They are being investigated to address limitations of conventional CAR-T therapy, especially the challenge of treating solid tumors.
Source:
addresses limitations of conventional CAR-T therapy including challenges in solid tumors
Source:
The tool is intended to improve treatment of hard-to-treat solid malignancies by combining direct tumor targeting with macrophage-mediated microenvironment remodeling. It is positioned as a potential alternative to existing cell-based therapies.
Source:
providing a potential alternative cell-based therapy for solid tumors
Source:
They are presented as part of a targeted therapeutic strategy beyond conventional immunosuppression.
Source:
targeted immune-cell-based intervention in autoimmune disease
Problem links
addresses limitations of conventional CAR-T therapy including challenges in solid tumors
LiteratureThey are being investigated to address limitations of conventional CAR-T therapy, especially the challenge of treating solid tumors.
Source:
They are being investigated to address limitations of conventional CAR-T therapy, especially the challenge of treating solid tumors.
extends CAR engineering to macrophage-based cell therapy
LiteratureThey represent an alternative immune-cell chassis within the CAR-engineering landscape.
Source:
They represent an alternative immune-cell chassis within the CAR-engineering landscape.
providing a potential alternative cell-based therapy for solid tumors
LiteratureThe tool is intended to improve treatment of hard-to-treat solid malignancies by combining direct tumor targeting with macrophage-mediated microenvironment remodeling. It is positioned as a potential alternative to existing cell-based therapies.
Source:
The tool is intended to improve treatment of hard-to-treat solid malignancies by combining direct tumor targeting with macrophage-mediated microenvironment remodeling. It is positioned as a potential alternative to existing cell-based therapies.
targeted immune-cell-based intervention in autoimmune disease
LiteratureThey are presented as part of a targeted therapeutic strategy beyond conventional immunosuppression.
Source:
They are presented as part of a targeted therapeutic strategy beyond conventional immunosuppression.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
manufacturingsignalingtranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
The approach requires macrophage genetic engineering and a manufacturing process that can address restricted cell expansion and product-quality variability. Clinical translation also depends on technological innovations that support a more versatile off-the-shelf product.; requires genetic engineering of macrophages; product quality control is a challenge; cell expansion is restricted; antigen selection is critical; co-stimulatory domain design is important; safety control mechanisms are important
The abstract indicates that CAR-M therapies still face several challenges in clinical application.; still face several challenges in clinical application; The abstract does not claim that current CAR-M approaches have solved manufacturing and translation barriers. Instead, it explicitly notes challenges in expansion, engineering complexity, and product consistency.; restricted cell expansion; genetic engineering complexities; variability in product quality; clinical translation remains challenging; The abstract does not provide direct validation details for this modality and notes broader translational challenges.; clinical translation is challenged by antigen specificity; clinical translation is challenged by long-term persistence; clinical translation is challenged by manufacturing feasibility
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2025MED
Source 3primary paper2026MED
Source 4primary paper2025MED
Ranked Claims
CAR-NK approaches are being used to target HIV.
CAR-NK approaches targeting HIV
CAR-Tregs enhance transplant tolerance.
CAR-Tregs enhancing transplant tolerance
CD19/BCMA-targeted CAR-T cells have achieved long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression.
CD19/BCMA-targeted CAR-T cells achieving long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression
Senolytic CARs reduce tissue fibrosis.
senolytic CARs reducing tissue fibrosis
CAR-NK cells and CAR-γδ T cells exhibit HLA-independent cytotoxicity and are promising off-the-shelf therapeutic options.
Notably, CAR-NK and CAR-γδ T cells exhibit HLA-independent cytotoxicity, making them promising 'off-the-shelf' therapeutic options.
Logic-gated CARs are highlighted as an innovation in next-generation CAR therapy design.
Innovations like off-the-shelf allogeneic products and logic-gated CARS are highlighted
Off-the-shelf allogeneic CAR products are highlighted as an innovation in CAR-engineered therapies.
Innovations like off-the-shelf allogeneic products and logic-gated CARS are highlighted
Conventional CAR-T therapy has complex manufacturing and severe treatment-related toxicities that limit broader clinical application.
The complex manufacturing process and severe treatmentrelated toxicities further limit its broader clinical application. To address these challenges, researchers are investigating alternative CAR-engineered immune cells
CAR-macrophages phagocytose tumor cells, present antigens, and remodel the immunosuppressive tumor microenvironment.
Meanwhile, CAR-M not only phagocytose tumor cells and present antigens but also remodel the immunosuppressive tumor microenvironment.
The CAR-engineered therapy landscape includes CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Alternative CAR-engineered immune-cell therapies still face several challenges in clinical application.
Despite their potential, these innovative therapies still face several challenges in clinical application.
CAR-macrophages may serve as an alternative to existing cell-based therapies.
making them a potential alternative to existing cell-based therapies
Technological innovations are needed to enable CAR-macrophage clinical success as a versatile off-the-shelf immunotherapy for hard-to-treat solid malignancies.
technological innovations necessary to facilitate clinical success as a versatile, off the shelf immunotherapy for hard-to-treat solid malignancies
Pre-clinical and clinical evidence suggests that CAR-macrophage therapy has significant promise for treating solid tumors.
Pre-clinical and clinical evidence suggests that CAR-M therapy holds significant promise for treating solid tumors.
Clinical translation of CAR-macrophage therapy is challenged by restricted cell expansion, genetic engineering complexities, and variability in product quality.
However, its clinical translation remains challenging due to restricted cell expansion, genetic engineering complexities, and variability in product quality.
CAR-macrophages can remodel the tumor microenvironment and directly target tumor cells through CAR signaling.
CAR-Ms can actively remodel the tumor microenvironment while directly targeting tumor cells through CAR signaling
The review covers CAR-T cells, CAR-Tregs, CAAR-T cells, CAR-NK cells, and CAR-macrophages as CAR-based approaches for autoimmune diseases.
CAR-macrophages are a promising immunotherapy approach for solid tumors.
Chimeric antigen receptor macrophages (CAR-Ms) represent a promising frontier in immunotherapy, leveraging both innate and engineered capabilities to combat solid tumors.
Approval Evidence
4 sources11 linked approval claimsfirst-pass slug car-macrophages
CARmacrophages (CAR-M) ... not only phagocytose tumor cells and present antigens but also remodel the immunosuppressive tumor microenvironment
Source:
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Source:
CAR-macrophages
Source:
Chimeric antigen receptor macrophages (CAR-Ms) represent a promising frontier in immunotherapy, leveraging both innate and engineered capabilities to combat solid tumors.
Source:
limitationsupports
Conventional CAR-T therapy has complex manufacturing and severe treatment-related toxicities that limit broader clinical application.
The complex manufacturing process and severe treatmentrelated toxicities further limit its broader clinical application. To address these challenges, researchers are investigating alternative CAR-engineered immune cells
Source:
mechanismsupports
CAR-macrophages phagocytose tumor cells, present antigens, and remodel the immunosuppressive tumor microenvironment.
Meanwhile, CAR-M not only phagocytose tumor cells and present antigens but also remodel the immunosuppressive tumor microenvironment.
Source:
modality diversificationsupports
The CAR-engineered therapy landscape includes CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Source:
translational limitationsupports
Alternative CAR-engineered immune-cell therapies still face several challenges in clinical application.
Despite their potential, these innovative therapies still face several challenges in clinical application.
Source:
comparative positioningsupports
CAR-macrophages may serve as an alternative to existing cell-based therapies.
making them a potential alternative to existing cell-based therapies
Source:
development goalsupports
Technological innovations are needed to enable CAR-macrophage clinical success as a versatile off-the-shelf immunotherapy for hard-to-treat solid malignancies.
technological innovations necessary to facilitate clinical success as a versatile, off the shelf immunotherapy for hard-to-treat solid malignancies
Source:
evidence summarysupports
Pre-clinical and clinical evidence suggests that CAR-macrophage therapy has significant promise for treating solid tumors.
Pre-clinical and clinical evidence suggests that CAR-M therapy holds significant promise for treating solid tumors.
Source:
limitationsupports
Clinical translation of CAR-macrophage therapy is challenged by restricted cell expansion, genetic engineering complexities, and variability in product quality.
However, its clinical translation remains challenging due to restricted cell expansion, genetic engineering complexities, and variability in product quality.
Source:
mechanism of actionsupports
CAR-macrophages can remodel the tumor microenvironment and directly target tumor cells through CAR signaling.
CAR-Ms can actively remodel the tumor microenvironment while directly targeting tumor cells through CAR signaling
Source:
modality scopesupports
The review covers CAR-T cells, CAR-Tregs, CAAR-T cells, CAR-NK cells, and CAR-macrophages as CAR-based approaches for autoimmune diseases.
Source:
therapeutic potentialsupports
CAR-macrophages are a promising immunotherapy approach for solid tumors.
Chimeric antigen receptor macrophages (CAR-Ms) represent a promising frontier in immunotherapy, leveraging both innate and engineered capabilities to combat solid tumors.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.; The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Source-backed strengths
presented as part of modality diversification; phagocytose tumor cells; present antigens; remodel the immunosuppressive tumor microenvironment; combines innate macrophage functions with engineered CAR targeting; can remodel the tumor microenvironment while directly targeting tumor cells
Source:
presented as part of modality diversification
Source:
phagocytose tumor cells
Source:
present antigens
Source:
remodel the immunosuppressive tumor microenvironment
Source:
combines innate macrophage functions with engineered CAR targeting
Source:
can remodel the tumor microenvironment while directly targeting tumor cells
Compared with CAAR-T cells
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with CAR-engineered macrophages
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.
Compared with CAR-MΦ
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Compared with CAR-NK
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with CAR-NK cells
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with CAR-NKT cells
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Compared with CAR-T
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with CAR-T cells
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with CAR-T cell therapy
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with CAR-Tregs
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with CAR-T therapy
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with chimeric antigen receptor macrophage
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.
Compared with chimeric antigen receptor macrophages
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.
Compared with chimeric antigen receptor natural killer cells
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with chimeric antigen receptor T cells
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with Chimeric antigen receptor T-cell therapy
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract mentions CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-NK cells as related alternatives.
Compared with HER2-targeting CAR-M
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.; The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.; The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as part of modality diversification; phagocytose tumor cells; present antigens.
Relative tradeoffs: still face several challenges in clinical application; restricted cell expansion; genetic engineering complexities.
Source:
The abstract contrasts CAR-macrophages with CAR-T, CAR-NK, and CAR-NKT cells.
Source:
The review compares CAR-macrophages with conventional CAR-T therapy and with CAR-NK and CAR-γδ T-cell platforms.
Source:
The abstract contrasts CAR-Ms with existing cell-based therapies, presenting CAR-Ms as a potential alternative. No specific alternative platform is named in the abstract.
Ranked Citations
- 1.
- 2.
- 3.
- 4.